Efficacy and safety of immune checkpoint inhibitors in a Danish real life non-small cell lung cancer population: a retrospective cohort study
Efficacy and safety of immune checkpoint inhibitors in a Danish real life non-small cell lung cancer population: a retrospective cohort study
复制标题
DOI：
10.1080/0284186x.2019.1615636
复制
发表时间：
2019-05-12
期刊：
影响因子：
3.1
通讯作者：
Schytte, Tine
中科院分区：
文献类型：
--
作者：
Bjornhart, Birgitte;Hansen, Karin H.;Schytte, Tine
背景：研究免疫检查点抑制(ICI)在丹麦非小细胞肺癌(NSCLC)人群中的疗效和毒性。通过纳入临床试验中代表性不足的患者，如脑转移(BM)、年龄较高、合并疾病较多和表现状态较差(ECOG)的患者，可以将未入选患者与临床试验人群进行比较。材料和方法：从2015年9月至2018年4月在丹麦欧登塞大学医院肿瘤科接受ICI治疗的118名不治之症NSCLC患者的真实生活数据收集。免疫相关不良事件(IrAEs)3-5级在同一时期进行了前瞻性登记。其他与患者相关的数据是从患者的档案中回溯获得的。结果：BM患者的中位年龄分别为66岁(IQR59-71)和62岁(55-)。女性63%；腺癌/鳞癌/其他69%/23%/8%；ECOG210%；骨/脑/肝转移36%/18%/15%；PD-L1(TPS)
Background: To investigate effect and toxicity of immune checkpoint inhibition (ICI) in a Danish real-life non-small cell lung cancer (NSCLC) population. By including patients underrepresented in clinical trials, such as those with brain metastasis (BM), higher age, more comorbidity and poorer performance status (ECOG), comparison of unselected patients to clinical trial populations is possible.Material and methods: Real life data were gathered from 118 consecutive NSCLC patients with incurable NSCLC treated with ICI at the Department of Oncology at the University Hospital of Odense, Denmark from September 2015 to April 2018. Immune-related adverse events (irAEs) grades 3-5 were registered prospectively during the same period. Additional patient related data were obtained retrospectively from patients' files. Overall survival (OS) and progression-free survival (PFS) were calculated using the Kaplan-Meier estimates, the log-rank test and cox regression analysis performed for factors affecting survival.Results: Median age for patients was 66 years (IQR 59-71) and 62 years (range: 55-64) for those with BM. Females 63%; adenocarcinoma (AC)/squamous/others 69%/23%/8%; ECOG 2 10%; bone/brain/liver metastases 36%/18%/15%; PD-L1 (TPS)